Literature DB >> 1968102

Osteoporosis associated with neuroleptic treatment. A case report.

J Kartaginer1, K Ataya, A Mercado, A Abbasi.   

Abstract

A 28-year-old woman developed osteoporosis following seven years of neuroleptic use. She presented with amenorrhea and profuse galactorrhea of four years' duration. Dual photon absorptionometry demonstrated reduced bone mineral density in the femur and spine. Serum calcium, phosphorus and alkaline phosphatase were normal. The patient was started on bromocriptine, and her bone density, serum prolactin, dehydroepiandrosterone sulfate, and free and total testosterone improved. No deterioration in her psychiatric condition occurred.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968102

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  4 in total

1.  Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.

Authors:  S R Tollin
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

2.  Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients.

Authors:  Jenn-Huei Renn; Nan-Ping Yang; Pesus Chou
Journal:  BMC Musculoskelet Disord       Date:  2010-02-17       Impact factor: 2.362

Review 3.  Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation.

Authors:  Uriel Halbreich
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Bone mass in schizophrenia and normal populations across different decades of life.

Authors:  Jenn-Huei Renn; Nan-Ping Yang; Ching-Mo Chueh; Chih-Yuan Lin; Tsuo-Hung Lan; Pesus Chou
Journal:  BMC Musculoskelet Disord       Date:  2009-01-01       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.